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Commencing and changing 
antidepressants
By Dr Michelle Bellingan
counselling in practice
Case study
Agnes (43 years old) is a long-standing 
customer at your pharmacy. Her 
husband passed away suddenly 
two years ago and she has three 
teenage boys. She is an office 
manager and has previously told you 
that she leads a largely sedentary 
lifestyle because she ‘doesn’t have 
time to exercise’. Agnes now tells 
you that ‘over the past couple of 
months everything has just become 
too much to cope with’. She has 
lost weight and is having trouble 
sleeping. Her doctor has diagnosed 
depression and Agnes presents you 
with a prescription for fluoxetine 
20 mg each morning. Agnes has never 
taken an antidepressant before and 
asks numerous questions regarding 
depression and her medication.
Can you tell me more about 
depression?
Depression is a large cause of 
disability in Australia.1 According to 
the 2007 National Survey of Mental 
Learning objectives 
After reading this article you should 
be able to:
• Describe signs and symptoms of 
depression.
• Provide appropriate advice 
to patients commencing 
antidepressant therapy.
• Provide appropriate advice 
to patients changing 
antidepressants. 
• Recognise symptoms that 
warrant immediate referral 
to a doctor.
Competencies addressed: 
2.1.1, 3.1.4, 3.2.2, 4.3.3, 7.3.2
Health and Wellbeing, 4.1% 
of adults have a depressive 
disorder in any given month.2 
It is further estimated that 
about one in five people will 
experience at least a short period 
of depression at some stage in 
their life.3 Depression occurs 
more commonly in women than 
men and most major depression 
begins in the late twenties.4
Many factors protect against, 
predispose to, or precipitate 
depression, including: genes, 
childhood experience, previous 
trauma, social and cultural 
supports, physical factors (including 
drugs) and stress.5
The symptoms of depression 
vary in severity from person 
to person. Table 1 summarises 
common symptoms of depression 
that range from feeling irritable 
to suicidal.3 Despite depression 
manifesting in different ways, 
most people with depression 
experience significant disruption 
to their normal lifestyle.6
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Table 1. Common symptoms 
of depression3
Emotional symptoms
• pervasive sadness
• irritable mood
• low, depressed mood
• loss of enjoyment or pleasure
• being aggressive or angry.
Cognitive symptoms
• worrying
• feeling worthless
• feeling hopeless
• thinking about death frequently
• guilt, self blame
• indecision.
Physical symptoms
• inability to concentrate
• fatigue or low energy nearly every 
day
• significant change in weight or 
appetite
• difficulty sleeping or excessive 
sleeping 
• increased sensitivity to pain
• agitation.
Social symptoms
• withdrawing or deliberately 
isolating yourself.
In the majority of cases, the prognosis 
for depression, where the person 
is being treated appropriately, 
is generally good. Studies have, 
however, identified that the probability 
of remission declines with increasing 
episode duration. Long term prognosis 
(i.e. probability of remission at 
six months and beyond) is strongly 
related to remission status at three 
months and only modestly related to 
various other clinical characteristics 
assessed at baseline (e.g. prior history 
of refractory depression, medical 
comorbidity and comorbid anxiety 
symptoms).7 A patient’s response to 
an antidepressant should therefore 
be assessed at three months. Should 
minimal improvement be evident, 
a change in antidepressant should 
be considered.
How do antidepressants 
work? How long will it take 
before I start feeling better?
The Monoamine Hypothesis states 
that depression is caused by a 
deficiency of monoamines, particularly 
noradrenaline and serotonin, in 
the synaptic cleft. According to 
this hypothesis, depression can be 
alleviated by drugs that increase 
the availability of noradrenaline 
and serotonin. The Monoamine 
Hypothesis cannot, however, 
explain the delay in time of onset of 
antidepressants. This is explained by 
the Receptor Sensitivity Hypothesis. 
Super sensitivity is a compensatory 
response of the postsynaptic neuron 
when it receives too little stimulation 
due to a deficiency of noradrenaline 
and serotonin. Over time, the 
postsynaptic neuron increases 
receptor responsiveness and may also 
compensate for the lack of stimulation 
by synthesising additional receptor 
sites. This upregulated postsynaptic 
state is believed to be associated with 
the clinical symptoms of depression.8
Via various pharmacodynamic 
actions, all antidepressants increase 
neurotransmitter levels in the 
synaptic cleft which then prompts a 
down-regulation and desensitisation 
of postsynaptic receptors.
Although neurotransmitter levels 
increase rapidly after taking an 
antidepressant, post-synaptic receptor 
down-regulation takes a number 
of weeks. Pharmacists should take 
care to explain that antidepressant 
therapeutic effects are not immediate. 
Unrealistic expectations of how soon 
a patient will start feeling ‘better’ only 
compound the depressed patient’s 
sense of hopelessness. 
How must I take/use the 
antidepressant? 
Antidepressants should be taken 
regularly every day. It should be made 
clear to patients that antidepressant 
medications should be taken for a 
minimum of two to four weeks for a 
noticeable therapeutic effect9 and that 
self-administration of higher doses will 
not result in a faster outcome. On the 
contrary, higher than prescribed doses 
will result in the amplification of side-
effects, some of which are potentially 
dangerous.
Some antidepressants are highly 
sedative, whereas others may 
increase alertness. It is therefore 
important to take the medication as 
advised by a doctor or pharmacist 
(i.e. at night or in the morning). 
Should a dose be missed and the 
patient remembers when it is almost 
time for the next dose, the dose 
should be skipped and the next dose 
taken at the usual time. Patients 
should be advised to not take a double 
dose to make up for the dose they 
have missed.10
Patients should also be counselled 
to continue taking the medicine 
even if feeling better and not 
to discontinue therapy without 
consulting their doctor.
Will I have to take 
antidepressants for the rest 
of my life? Will I get addicted 
to them?
After a patient’s first episode of 
major depression antidepressant 
therapy needs to continue for four to 
12 months for maximum efficacy.11 
Treatment should continue for at least 
two years for repeated episodes or 
where there are other risk factors 
for relapse.6 In the majority of cases 
of recurrent depression, continuous 
maintenance antidepressant treatment 
may be required.11
Concern about the addiction potential 
of antidepressants has arisen from 
an increasing volume of research 
characterising a withdrawal syndrome 
on cessation of treatment.12,13 
Such symptoms typically appear one 
to three days after termination of 
treatment and last seven to 14 days.14
The DSM-IV lists seven criteria that 
represent substance dependence.4 
To qualify for a diagnosis of substance 
dependence, an individual must 
meet at least three of these criteria. 
Withdrawal symptoms are only one 
criterion for dependence, and alone 
are not sufficient for a diagnosis 
of dependence. The essence of 
dependence is drug-seeking behaviour 
despite negative consequences – 
this behaviour is not apparent on 
cessation of an antidepressant.15
It is important to address 
Agnes’ concerns regarding 
‘addiction’ since non-adherence 
to medications is a significant 
barrier to the effective treatment of 
depression. Discontinuation rates 
of antidepressants within three 
months of treatment initiation can 
reach 68%.16
Are antidepressants 
safe to take?
Side-effects vary depending on which 
antidepressant the patient has been 
prescribed. Common side-effects 
are outlined in Table 2. Studies have 
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shown that fear of side-effects 
and the actual occurrence of side-
effects are the main reasons for not 
filling a second prescription of an 
antidepressant.17 Since side-effects 
tend to manifest shortly after initiating 
therapy (while the therapeutic effects 
are delayed), it is vitally important that 
patients are made aware of common 
side-effects and their expected 
duration and, where possible, 
counselled on practical measures to 
manage side-effects.
The risk of suicide is inherent in 
depression and may persist until 
significant remission occurs. Patients 
should be closely monitored for 
clinical worsening and suicidality 
(suicidal ideation and suicidal 
behaviours), especially at the 
beginning of a course of treatment, 
or at the time of dose changes, either 
increases or decreases. Symptoms 
of anxiety, agitation, panic attacks, 
insomnia, irritability, hostility, 
impulsivity, akathisia, hypomania and 
mania have been reported in patients 
being treated with antidepressants. 
Although a causal link between the 
emergence of such symptoms and 
either worsening of depression and/
or emergence of suicidality impulses 
has not been established, there is 
concern that such symptoms may be 
precursors of emerging suicidality. 
Patients (and caregivers of patients) 
should be alerted about the need to 
monitor for any worsening of their 
condition and/or the emergence 
of suicidal ideation or behaviour or 
thoughts of harming themselves and 
to seek medical advice immediately 
if these symptoms present. 
Consideration should be given to 
changing the therapeutic regimen, 
including possibly discontinuing the 
antidepressant, in patients whose 
depression is persistently worse or 
whose emergent suicidality is severe, 
abrupt in onset, or was not part of the 
patient’s presenting symptoms.19
The risk of serotonin syndrome 
is another important point to be 
addressed in patients prescribed 
antidepressant therapy. Serotonin 
toxicity is characterised by 
neuromuscular excitation (clonus, 
hyperreflexia, myoclonus, rigidity), 
autonomic stimulation (hyperthermis, 
tachycardia, diaphoresis, tremor, 
flushing) and changed mental state 
(anxiety, agitation, confusion). There 
are several drug mechanisms that 
cause excess serotonin in the central 
nervous system, but severe serotonin 
toxicity only occurs with combinations 
of drugs acting at different sites, most 
commonly a monoamine oxidase 
inhibitor and a serotonin reuptake 
inhibitor. Less severe toxicity occurs 
with other combinations, overdoses 
and even single-drug therapy in 
susceptible individuals. To minimise 
the risk of serotonin toxicity, patients 
taking antidepressants should be 
counselled to always advise their 
doctor or pharmacist prior to initiating 
any new prescription or over-the-
counter drugs. Patients should also be 
aware that certain recreational drugs 
(e.g. amphetamines and ecstasy) are 
serotonin-releasing drugs and pose 
the risk of serotonin toxicity if taken 
concurrently with antidepressants.20
What if the antidepressant 
doesn’t help me?
Despite antidepressants being 
effective in the treatment of 
depression, non-response remains a 
major clinical problem. It is reported 
that 30% of patients do not respond 
to antidepressants at all, while 
another 30% respond only partially 
without reaching full remission.21
Patients who report an unsatisfactory 
response to initial antidepressant 
treatment should be re-assessed in 
terms of their diagnosis and treatment 
plan. Lack of adherence to the 
treatment plan should be considered 
and perpetuating psychosocial factors 
need to be reviewed.22 The following 
measures may be considered in 
patients who fail to respond to initial 
antidepressant therapy: a change in 
antidepressant, psychotherapy or 
lifestyle measures (e.g. exercise, 
meditation, relaxation techniques, 
stress management, support groups 
and self-help programmes). Should a 
second antidepressant also fail to elicit 
a response, augmentation with lithium 
may be considered. Electroconvulsive 
therapy (ECT) should be reserved for 
severe, refractory depression.1,2,22
My GP has recommended 
I see a counsellor. Do you 
think it would be worth going 
if these tablets are going to 
make me feel better anyway?
Various psychotherapies are available 
as sole treatments or adjuncts 
to antidepressant medication. 
Interpersonal therapy, cognitive-
behavioural therapy, behavioural 
therapy and brief dynamic therapy 
have all been used in the treatment 
of mild to moderate depression. 
Antidepressants can eliminate many 
of the symptoms of depression, 
whereas psychotherapy is best 
at assisting the patient in day-
to-day coping skills that can 
prevent relapse.24
Cognitive-behavioural therapy (or, 
to a lesser extent, interpersonal 
therapy) plus medication is reported 
to give better results than either 
treatment alone25 for depression or 
for comorbid anxiety and depressive 
disorders.26 Despite the combination 
of medication and psychotherapy 
yielding good results, patients 
with severe depression require 
antidepressant therapy or ECT 
prior to engaging in meaningful 
psychotherapy.22 
Would increasing my 
physical activity help me feel 
better?
Feeling tired and demotivated are 
common symptoms of depression. 
Exercise is often the last thing 
individuals feel like doing when 
they are depressed. Studies have, 
however, shown that individuals 
who exercise regularly experience 
fewer symptoms of depression 
and anxiety than those who do not 
exercise regularly. Research also 
suggests that exercise can further 
assist depression in individuals 
who have responded only partially 
to an antidepressant.27 In this 
particular scenario, Agnes should be 
encouraged to build up her physical 
activity gradually. She could start 
with a 10–15 minute walk each 
morning and gradually increase this 
to 30 minutes per day.
Case study 
Agnes returns to your pharmacy after 
three months fluoxetine therapy. 
Her doctor has now changed her 
treatment to mirtazapine 15 mg at 
night. Agnes informs you that the 
fluoxetine made her feel ‘dreadful’. 
She was ‘very anxious, had recurrent 
headaches and experienced more 
trouble sleeping than before’. Agnes 
also reports attending a single 
counselling session. She ‘felt no 
different’ after spending an hour with 
the counsellor and has never returned.
counselling in practice
Vol. 29 – July #07
579
C
o
n
tin
u
in
g
 P
ro
fe
s
s
io
n
a
l D
e
v
e
lo
p
m
e
n
t
Submit your answers online at www.psa.org.au and receive automatic feedback
How should I change from 
my previous antidepressant 
to this new one?
When changing from one 
antidepressant to another, the 
need for a wash-out period should 
always be considered. The absence 
of a wash-out period can lead to 
serious adverse effects due to 
the interaction between the initial 
antidepressant and the subsequently 
prescribed drug. Of particular 
concern is the risk of serotonin 
syndrome. Table 3 outlines the 
recommendations for antidepressant 
changeover.
In this particular scenario, Agnes 
should be counselled to stop 
taking the fluoxetine capsules for 
10–14 days before initiating the 
mirtazapine therapy. Fluoxetine’s 
very long half-life would minimise 
the risk of withdrawal symptoms. 
Re-emphasise the benefits of 
psychotherapy as an adjunctive 
therapy to the antidepressant and 
explain that the benefits of therapy 
are not immediately apparent.
Where can I find more 
information on depression?
Table 4 provides the details of some 
of the organisations patients may be 
referred to for further information. 
Depressed individuals in urgent need 
of assistance should be encouraged to 
call Lifeline on 13 11 14.
Table 4. Useful Websites3
www.beyondblue.org.au 
Information on depression, anxiety 
and bipolar disorder
www.blackdoginstitute.org.au 
Specialist information on depression 
and bipolar disorder
www.depressionservices.org.au 
Information and online forums with 24 
hour peer support and moderation for 
individuals living with depression
Key learning points
• Since poor adherence is a 
major problem with the use of 
antidepressants, pharmacists 
can play a vital role in counselling 
patients on the expected time to 
therapeutic onset and potential 
adverse effects (particularly 
those likely to present on 
commencement of treatment).
• The adjunctive role of 
psychotherapy and positive lifestyle 
interventions in the management 
of depression should be explained 
and encouraged.
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Category C changeover
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Moclobemide
Reboxetine
Venlafaxine
Desvenlafaxine
• duloxetine, venlafaxine, 
desvenlafaxine; withdraw gradually to 
prevent withdrawal symptoms
• reboxetine, moclobemide: withdrawal 
symptoms not reported
• wait for 1–2 days before starting the 
next antidepressant
Drug (or 
metabolites) with 
short half-life of 
< 18 hours
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1. After a patient’s first 
major depressive episode 
antidepressant therapy needs 
to continue for a minimum of: 
a) 2 years.
b) 1 year.
c) 4 months.
d) 2 months.
2. Which of the following is not 
a potential adverse effect 
experienced in patients 
commencing a SSRI?
a) Headache.
b) Constipation.
c) Increased anxiety/agitation.
d) Transient nausea.
3. Which of the following 
antidepressant regimens 
is least likely to result in a 
withdrawal syndrome upon 
discontinuation?
a) Desvenlafaxine 50 mg daily.
b) Clomipramine 200 mg daily.
c) Fluoxetine 40 mg daily.
d) Paroxetine 20 mg daily.
4. Identify the correct process 
whereby a moderately 
depressed patient’s therapy is 
changed from moclobemide 
to venlafaxine.
a) Gradually withdraw moclobemide 
over a period of one week; wait for 
a further 1–2 days before starting 
venlafaxine.
b) No need to gradually withdraw 
moclobemide; it may be 
discontinued and venlafaxine 
started within 1–2 days.
c) Gradually withdraw moclobemide 
over a period of one week; wait 
for a further 10–14 days before 
starting venlafaxine.
d) Gradually withdraw moclobemide 
over a period of one week; wait 
for a further 2–4 days before 
starting venlafaxine.
5. Which of the following 
statements would be incorrect 
when counselling a patient 
on the commencement of an 
antidepressant?
a) Adverse effects are likely to 
be experienced prior to any 
therapeutic benefits.
b) It is important to catch up missed 
doses – even if this means 
doubling up the dose when 
you remember.
c) Report any worsening depression 
or suicidal feelings to your doctor.
d) Do not stop taking the 
antidepressant at your 
own discretion.
Questions  A score of 4 out of 5 attracts 1 credit point.
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